Your browser doesn't support javascript.
loading
Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors.
Zhai, Yinghong; Hu, Fangyuan; Shi, Wentao; Ye, Xiaofei; Xu, Jingfang; Guo, Xiaojing; Cao, Yang; He, Jia; Xu, Feng.
Affiliation
  • Zhai Y; Clinical Research Center, School of Medicine, Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University, Shanghai, China.
  • Hu F; Department of Medical Service, Naval Hospital of Eastern theater, Zhejiang, Zhoushan, China.
  • Shi W; Department of Health Statistics, Second Military Medical University, Shanghai, China.
  • Ye X; Clinical Research Center, School of Medicine, Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University, Shanghai, China.
  • Xu J; Department of Health Statistics, Second Military Medical University, Shanghai, China.
  • Guo X; Department of Health Statistics, Second Military Medical University, Shanghai, China.
  • Cao Y; Department of Health Statistics, Second Military Medical University, Shanghai, China.
  • He J; Department of Health Statistics, Second Military Medical University, Shanghai, China.
  • Xu F; Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden.
Expert Opin Drug Saf ; 22(9): 857-869, 2023.
Article in En | MEDLINE | ID: mdl-37070462

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Heart Diseases Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Expert Opin Drug Saf Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2023 Type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Heart Diseases Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Expert Opin Drug Saf Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2023 Type: Article Affiliation country: China